Mdxhealth GPS-ProMPT study published in European Urology Oncology
Mdxhealth has announced the peer-reviewed publication of the Oxford GPS-ProMPT study in European Urology Oncology, a leading journal in genitourinary oncology. The publication marks the first major peer-reviewed output from the company's collaboration with the University of Oxford and is intended to provide the scientific grounding for the ongoing GPS-ProtecT randomised controlled trial.
The GPS-ProMPT study followed 409 men with localised or locally advanced prostate cancer over more than six years, evaluating the company's GPS mdx genomic classifier across three treatment pathways: active surveillance, radical prostatectomy, and radiotherapy. Patients with favourable GPS mdx scores recorded strong long-term outcomes, including 92% freedom-from-failure at six years among those on active surveillance and up to 100% in surgery and radiotherapy cohorts, even where adverse clinical risk factors were present.
Lead author Dr Nikita Sushentsev, of Cambridge University Hospitals NHS Foundation Trust, said the findings suggest the test "can identify favourable tumour biology that traditional risk stratification alone would miss, with meaningful implications for how we counsel patients facing treatment decisions."
The ProtecT connection
The GPS-ProtecT study, initiated in January 2026, applies GPS mdx testing to the long-running UK ProtecT trial, widely described as the world's largest randomised clinical trial of treatment effectiveness in localised prostate cancer. That trial has followed more than 1,500 men for over two decades, generating outcome data across active surveillance, radical prostatectomy, and radiotherapy. Mdxhealth is positioning GPS mdx as the first genomic classifier that could be supported by level-one randomised trial evidence in an active surveillance cohort. If the GPS-ProtecT study delivers on that goal, it would meaningfully strengthen the commercial case for the test by removing a frequent objection from payers and guideline bodies that current evidence is based on observational or retrospective cohorts.
GPS mdx is a 17-gene expression assay performed on prostate biopsy tissue. It estimates the risk of adverse pathology, high-grade disease, metastasis within ten years, and prostate cancer death, beyond what conventional clinical staging provides. The test was formerly commercialised as the Oncotype DX Prostate Score under a previous owner and already appears in several major prostate cancer clinical guidelines.
Market context
The genomic prostate cancer diagnostics segment has become increasingly competitive. Several genomic classifiers, including Decipher (Veracyte) and Prolaris (Myriad Genetics), are vying for a position in guideline-endorsed and payer-covered clinical pathways. Randomised trial data would mark a meaningful differentiation for GPS mdx, since most genomic classifiers in this space rely on retrospective validation cohorts rather than prospective controlled trial evidence. The National Institute for Health and Care Excellence and other health technology assessment bodies increasingly require robust prospective evidence to support reimbursement decisions, particularly in the NHS context where the ProtecT trial was conducted.
Chief executive Michael McGarrity said the publication "supports our advancement of GPS with regard to guideline development, payer coverage, and physician adoption," signalling that the company views the European Urology Oncology paper as a commercial as well as scientific milestone. For investors, the near-term watch points are the pace of enrolment and interim readouts from GPS-ProtecT, alongside any expansion of payer coverage decisions in the US market.